Tag: RNA Therapeutics
-

Novartis’ Del-desiran Fails Phase 3, Deepening a Week of Pipeline Setbacks
Novartis’ del-desiran missed the primary endpoint in the Phase 3 HARBOR trial for DM1, raising questions about the $12 billion Avidity acquisition and the clinical translation of its AOC platform.
-

FDA Approves Ionis’ Zanvastro as the First Treatment for Alexander Disease
The FDA approved Ionis’ Zanvastro as the first treatment for Alexander disease, validating GFAP-targeted antisense therapy in an ultra-rare neurological disorder.
-

Eli Lilly Moves Into Trans-Amplifying RNA Vaccines With Amplitude Deal
Eli Lilly is expanding into next-generation RNA vaccines through a collaboration with Amplitude Therapeutics, gaining access to a trans-amplifying RNA platform designed to separate the replicase from the antigen payload and support multiple infectious-disease vaccine programs.